Matches in Wikidata for { <http://www.wikidata.org/entity/Q91856407> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- Q91856407 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91856407 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91856407 description "scientific article published on 13 April 2020" @default.
- Q91856407 description "wetenschappelijk artikel" @default.
- Q91856407 description "наукова стаття, опублікована 13 квітня 2020" @default.
- Q91856407 name "EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes" @default.
- Q91856407 name "EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes" @default.
- Q91856407 type Item @default.
- Q91856407 label "EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes" @default.
- Q91856407 label "EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes" @default.
- Q91856407 prefLabel "EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes" @default.
- Q91856407 prefLabel "EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes" @default.
- Q91856407 P1433 Q91856407-7BA4EE2D-1AA0-408F-934A-6884FD740135 @default.
- Q91856407 P1476 Q91856407-40DCAB11-8EE5-4AF5-8A23-089AF57B8A5B @default.
- Q91856407 P2093 Q91856407-18405855-7932-4DEA-A3F1-A2DAA5F6D8E2 @default.
- Q91856407 P2093 Q91856407-21D1A724-F4CF-4D8E-9BF9-0E57A9349BA6 @default.
- Q91856407 P2093 Q91856407-4F71D50A-9DAA-40A2-B2A0-86FA95DD7F99 @default.
- Q91856407 P2093 Q91856407-8A7A6705-DE68-41F2-AC84-6DFC36711D54 @default.
- Q91856407 P2093 Q91856407-9276FC99-952E-4065-A466-F1F4EEE64769 @default.
- Q91856407 P2093 Q91856407-A033FCEF-BD6B-4A70-ABC0-E0F5D8C61915 @default.
- Q91856407 P2093 Q91856407-B3499EEB-24C5-47C2-B93D-B11B472C93B6 @default.
- Q91856407 P2093 Q91856407-C01193C3-5D53-40C9-A6D9-527A3D6648FE @default.
- Q91856407 P2093 Q91856407-C57DC420-B059-42A3-BEDB-7E970F8FF32A @default.
- Q91856407 P2093 Q91856407-D31CED0D-0087-4387-BA6F-30F2ACA263E4 @default.
- Q91856407 P2093 Q91856407-DE43144D-8323-4097-9E06-61ED710898BE @default.
- Q91856407 P2093 Q91856407-DE4A06B0-E1B1-459B-A811-06BA21542E1E @default.
- Q91856407 P2093 Q91856407-F49A1993-EFA3-4DF4-BB44-246A515A91F0 @default.
- Q91856407 P31 Q91856407-DEBFAB2A-C21F-4E18-ADDC-359EBBBDCE7C @default.
- Q91856407 P356 Q91856407-66745889-FF2A-4121-AB9E-9492D4ADCFB3 @default.
- Q91856407 P577 Q91856407-C23CBC39-3A6D-4B06-BB9C-A44130123457 @default.
- Q91856407 P698 Q91856407-A38CC9A1-59B7-49FA-8FAA-3F89BBCDC9F3 @default.
- Q91856407 P921 Q91856407-469D1083-9EDA-4F39-A1B1-AF4B0638CBF7 @default.
- Q91856407 P921 Q91856407-9F4DFABF-54F1-43F0-81B8-5723C8DD2937 @default.
- Q91856407 P921 Q91856407-DDF84363-C8A6-43BA-ABAE-B3578F5AE569 @default.
- Q91856407 P921 Q91856407-FB8C9EF7-F1BE-4C07-857D-4C28728911FB @default.
- Q91856407 P932 Q91856407-D969E6BA-3153-4A1F-820C-D0E4DCB06403 @default.
- Q91856407 P356 THEONCOLOGIST.2019-0785 @default.
- Q91856407 P698 32282100 @default.
- Q91856407 P1433 Q2122327 @default.
- Q91856407 P1476 "EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes" @default.
- Q91856407 P2093 "Beatriz Flores" @default.
- Q91856407 P2093 "Francesco Pignatti" @default.
- Q91856407 P2093 "Janet Koenig" @default.
- Q91856407 P2093 "João Freire" @default.
- Q91856407 P2093 "Karri Penttilä" @default.
- Q91856407 P2093 "Kyriaki Tzogani" @default.
- Q91856407 P2093 "Paola Coppola" @default.
- Q91856407 P2093 "Robert Hemmings" @default.
- Q91856407 P2093 "Silva Márcia" @default.
- Q91856407 P2093 "Silvia Domingo Roige" @default.
- Q91856407 P2093 "Susan Cole" @default.
- Q91856407 P2093 "Tuomo Lapveteläinen" @default.
- Q91856407 P2093 "Yolanda Barbachano" @default.
- Q91856407 P31 Q13442814 @default.
- Q91856407 P356 "10.1634/THEONCOLOGIST.2019-0785" @default.
- Q91856407 P577 "2020-04-13T00:00:00Z" @default.
- Q91856407 P698 "32282100" @default.
- Q91856407 P921 Q180983 @default.
- Q91856407 P921 Q411659 @default.
- Q91856407 P921 Q53910821 @default.
- Q91856407 P921 Q53948161 @default.
- Q91856407 P932 "7485353" @default.